Therapeutic Effect of γ-Secretase Inhibition in KrasG12V-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK

Cancer Cell

Volumn 22, Issue 2, 2012, Pages 222-234

  Maraver, Antonio ^a   Fernandez Marcos, Pablo J ^a   Herranz, Daniel ^a,d   Cañamero, Marta ^a   Muñoz Martin, Maribel ^a   Gómez López, Gonzalo ^a   Mulero, Francisca ^a   Megías, Diego ^a   Sanchez Carbayo, Marta ^a   Shen, Jie ^b   Sanchez Cespedes, Montserrat ^c   Palomero, Teresa ^d   Ferrando, Adolfo ^d   Serrano, Manuel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; K RAS PROTEIN; LSN 411575; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME REPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN BINDING; UPREGULATION;

EID: 84865201590     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.06.014     Document Type: Article

References (61)

1. Bateman R.J., Siemers E.R., Mawuenyega K.G., Wen G., Browning K.R., Sigurdson W.C., Yarasheski K.E., Friedrich S.W., Demattos R.B., May P.C., et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. 2009, 66:48-54.
2. Best J.D., Jay M.T., Otu F., Ma J., Nadin A., Ellis S., Lewis H.D., Pattison C., Reilly M., Harrison T., et al. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6- oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J. Pharmacol. Exp. Ther. 2005, 313:902-908.
3. Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M. A gene-alteration profile of human lung cancer cell lines. Hum. Mutat. 2009, 30:1199-1206.
4. Blasco R.B., Francoz S., Santamaría D., Cañamero M., Dubus P., Charron J., Baccarini M., Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011, 19:652-663.
5. Brondello J.M., Brunet A., Pouysségur J., McKenzie F.R. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J. Biol. Chem. 1997, 272:1368-1376.
6. Chen Y., De Marco M.A., Graziani I., Gazdar A.F., Strack P.R., Miele L., Bocchetta M. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007, 67:7954-7959.
7. Chiba S. Notch signaling in stem cell systems. Stem Cells 2006, 24:2437-2447.
8. Collins B.J., Kleeberger W., Ball D.W. Notch in lung development and lung cancer. Semin. Cancer Biol. 2004, 14:357-364.
9. Demarest R.M., Ratti F., Capobianco A.J. It's T-ALL about Notch. Oncogene 2008, 27:5082-5091.
10. Edbauer D., Winkler E., Haass C., Steiner H. Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation. Proc. Natl. Acad. Sci. USA 2002, 99:8666-8671.
11. Eliasz S., Liang S., Chen Y., De Marco M.A., Machek O., Skucha S., Miele L., Bocchetta M. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 2010, 29:2488-2498.
12. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
13. Espinosa L., Cathelin S., D'Altri T., Trimarchi T., Statnikov A., Guiu J., Rodilla V., Inglés-Esteve J., Nomdedeu J., Bellosillo B., et al. The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell 2010, 18:268-281.
14. Feldser D.M., Kostova K.K., Winslow M.M., Taylor S.E., Cashman C., Whittaker C.A., Sanchez-Rivera F.J., Resnick R., Bronson R., Hemann M.T., Jacks T. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010, 468:572-575.
15. Ferrando A.A. The role of NOTCH1 signaling in T-ALL. Hematology (Am Soc Hematol Educ Program) 2009, 2009:353-361.
16. Fischer B.M., Mortensen J., Højgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol. 2001, 2:659-666.
17. Fleisher A.S., Raman R., Siemers E.R., Becerra L., Clark C.M., Dean R.A., Farlow M.R., Galvin J.E., Peskind E.R., Quinn J.F., et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 2008, 65:1031-1038.
18. Fraering P.C. Structural and functional determinants of gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. Curr. Genomics 2007, 8:531-549.
19. Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., Owens D.K. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001, 285:914-924.
20. Guerra C., Mijimolle N., Dhawahir A., Dubus P., Barradas M., Serrano M., Campuzano V., Barbacid M. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003, 4:111-120.
21. Haruki N., Kawaguchi K.S., Eichenberger S., Massion P.P., Olson S., Gonzalez A., Carbone D.P., Dang T.P. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res. 2005, 65:3555-3561.
22. Hass M.R., Sato C., Kopan R., Zhao G. Presenilin: RIP and beyond. Semin. Cell Dev. Biol. 2009, 20:201-210.
23. Heitzler P. Biodiversity and noncanonical Notch signaling. Curr. Top. Dev. Biol. 2010, 92:457-481.
24. Iso T., Kedes L., Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J. Cell. Physiol. 2003, 194:237-255.
25. Ito T., Udaka N., Yazawa T., Okudela K., Hayashi H., Sudo T., Guillemot F., Kageyama R., Kitamura H. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 2000, 127:3913-3921.
26. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15:3243-3248.
27. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
28. Ji H., Wang Z., Perera S.A., Li D., Liang M.C., Zaghlul S., McNamara K., Chen L., Albert M., Sun Y., et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007, 67:4933-4939.
29. Junttila M.R., Karnezis A.N., Garcia D., Madriles F., Kortlever R.M., Rostker F., Brown Swigart L., Pham D.M., Seo Y., Evan G.I., Martins C.P. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2010, 468:567-571.
30. Kim M.Y., Park J.H., Choi E.J., Park H.S. Presenilin acts as a positive regulator of basal level activity of ERK through the Raf-MEK1 signaling pathway. Biochem. Biophys. Res. Commun. 2005, 332:609-613.
31. Konishi J., Kawaguchi K.S., Vo H., Haruki N., Gonzalez A., Carbone D.P., Dang T.P. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007, 67:8051-8057.
32. Liang M.C., Ma J., Chen L., Kozlowski P., Qin W., Li D., Goto J., Shimamura T., Hayes D.N., Meyerson M., et al. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 2010, 29:1588-1597.
33. Lin Y.W., Chuang S.M., Yang J.L. ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J. Biol. Chem. 2003, 278:21534-21541.
34. Luistro L., He W., Smith M., Packman K., Vilenchik M., Carvajal D., Roberts J., Cai J., Berkofsky-Fessler W., Hilton H., et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 2009, 69:7672-7680.
35. Maraver A., Tadokoro C.E., Badura M.L., Shen J., Serrano M., Lafaille J.J. Effect of presenilins in the apoptosis of thymocytes and homeostasis of CD8+ T cells. Blood 2007, 110:3218-3225.
36. Meylan E., Dooley A.L., Feldser D.M., Shen L., Turk E., Ouyang C., Jacks T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462:104-107.
37. Michie A.M., Chan A.C., Ciofani M., Carleton M., Lefebvre J.M., He Y., Allman D.M., Wiest D.L., Zúñiga-Pflücker J.C., Izon D.J. Constitutive Notch signalling promotes CD4 CD8 thymocyte differentiation in the absence of the pre-TCR complex, by mimicking pre-TCR signals. Int. Immunol. 2007, 19:1421-1430.
38. Morimoto M., Liu Z., Cheng H.T., Winters N., Bader D., Kopan R. Canonical Notch signaling in the developing lung is required for determination of arterial smooth muscle cells and selection of Clara versus ciliated cell fate. J. Cell Sci. 2010, 123:213-224.
39. Mulero F., Donate L.E., Serrano M. Imaging cancer in mice by PET, CT, and combined PET-CT. Curr Protoc Mouse Biol 2011, 1:85-103.
40. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
41. Palomero T., Sulis M.L., Cortina M., Real P.J., Barnes K., Ciofani M., Caparros E., Buteau J., Brown K., Perkins S.L., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 2007, 13:1203-1210.
42. Panza F., Solfrizzi V., Frisardi V., Imbimbo B.P., Capurso C., D'Introno A., Colacicco A.M., Seripa D., Vendemiale G., Capurso A., Pilotto A. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. Aging Clin. Exp. Res. 2009, 21:386-406.
43. Paris D., Quadros A., Patel N., DelleDonne A., Humphrey J., Mullan M. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur. J. Pharmacol. 2005, 514:1-15.
44. Patterson K.I., Brummer T., O'Brien P.M., Daly R.J. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J. 2009, 418:475-489.
45. Roy M., Pear W.S., Aster J.C. The multifaceted role of Notch in cancer. Curr. Opin. Genet. Dev. 2007, 17:52-59.
46. Sang L., Roberts J.M., Coller H.A. Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol. Med. 2010, 16:17-26.
47. Saura C.A., Choi S.Y., Beglopoulos V., Malkani S., Zhang D., Shankaranarayana Rao B.S., Chattarji S., Kelleher R.J., Kandel E.R., Duff K., et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004, 42:23-36.
48. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with " K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
49. Sweet-Cordero A., Mukherjee S., Subramanian A., You H., Roix J.J., Ladd-Acosta C., Mesirov J., Golub T.R., Jacks T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 2005, 37:48-55.
50. Tanigaki K., Han H., Yamamoto N., Tashiro K., Ikegawa M., Kuroda K., Suzuki A., Nakano T., Honjo T. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat. Immunol. 2002, 3:443-450.
51. Tsao P.N., Vasconcelos M., Izvolsky K.I., Qian J., Lu J., Cardoso W.V. Notch signaling controls the balance of ciliated and secretory cell fates in developing airways. Development 2009, 136:2297-2307.
52. van Es J.H., van Gijn M.E., Riccio O., van den Born M., Vooijs M., Begthel H., Cozijnsen M., Robine S., Winton D.J., Radtke F., Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963.
53. Vicent S., Garayoa M., López-Picazo J.M., Lozano M.D., Toledo G., Thunnissen F.B., Manzano R.G., Montuenga L.M. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin. Cancer Res. 2004, 10:3639-3649.
54. Weijzen S., Rizzo P., Braid M., Vaishnav R., Jonkheer S.M., Zlobin A., Osborne B.A., Gottipati S., Aster J.C., Hahn W.C., et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 2002, 8:979-986.
55. Wendorff A.A., Koch U., Wunderlich F.T., Wirth S., Dubey C., Brüning J.C., MacDonald H.R., Radtke F. Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity 2010, 33:671-684.
56. Westhoff B., Colaluca I.N., D'Ario G., Donzelli M., Tosoni D., Volorio S., Pelosi G., Spaggiari L., Mazzarol G., Viale G., et al. Alterations of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. USA 2009, 106:22293-22298.
57. Wolfe M.S. gamma-Secretase in biology and medicine. Semin. Cell Dev. Biol. 2009, 20:219-224.
58. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J.S., Lee H.J., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 2004, 279:12876-12882.
59. Wu J.J., Zhang L., Bennett A.M. The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Mol. Cell. Biol. 2005, 25:4792-4803.
60. Yang Y., Iwanaga K., Raso M.G., Wislez M., Hanna A.E., Wieder E.D., Molldrem J.J., Wistuba I.I., Powis G., Demayo F.J., et al. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE 2008, 3:e2220.
61. Zhang P., Yang Y., Nolo R., Zweidler-McKay P.A., Hughes D.P. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene 2010, 29:2916-2926.